Diagnostic Center | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
Subscribe To Our Newsletter & Stay Updated
